Hepatitis b virus hbsag surface protein antigen
Heplisav B, PreHevbri (hepatitis b virus hbsag surface protein antigen) is an unknown pharmaceutical. Hepatitis b virus hbsag surface protein antigen was first approved as Heplisav b on 2021-02-18. It has been approved in Europe to treat hepatitis b.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
235 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis b | D006509 | 11 | 16 | 42 | 28 | 19 | 111 | ||
| Hepatitis | D006505 | HP_0012115 | K75.9 | 1 | 4 | 3 | 11 | 2 | 20 |
| Healthy volunteers/patients | — | 5 | 2 | 9 | 2 | 3 | 20 | ||
| Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 2 | 7 | 2 | 2 | 5 | 16 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 2 | 2 | 2 | 6 | 15 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | 2 | 3 | 2 | 7 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | 1 | 1 | 1 | 2 | 5 |
| Hiv | D006678 | O98.7 | — | 1 | 2 | 1 | — | 3 | |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | 1 | — | 2 |
| Viral hepatitis human | D006525 | EFO_0004196 | — | — | 1 | 1 | — | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Whooping cough | D014917 | EFO_0000650 | A37 | — | 3 | 5 | — | 1 | 9 |
| Diphtheria | D004165 | EFO_0005549 | A36 | — | 3 | 6 | — | — | 9 |
| Tetanus | D013742 | EFO_0005593 | A35 | — | 3 | 4 | — | — | 7 |
| Poliomyelitis | D011051 | EFO_0007450 | A80 | — | 2 | 5 | — | — | 7 |
| Meningococcal infections | D008589 | EFO_0004249 | A39 | — | 3 | 1 | — | 1 | 5 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | 1 | 1 | — | 1 | 3 | |
| Liver transplantation | D016031 | EFO_0010682 | 1 | 2 | 1 | — | — | 3 | |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 2 | — | 1 | 3 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | 2 | — | 1 | 3 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | — | 1 | 2 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schistosomiasis | D012552 | EFO_1001475 | B65 | 2 | 1 | — | — | — | 2 |
| Measles | D008457 | B05 | — | 1 | — | — | 1 | 2 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | — | — | — | 2 |
| Schistosoma mansoni | D012550 | NCBITaxon_6183 | 1 | 1 | — | — | — | 1 | |
| Meningitis | D008581 | EFO_0000584 | G03 | — | 1 | — | — | — | 1 |
| Mumps | D009107 | B26 | — | 1 | — | — | — | 1 | |
| Chickenpox | D002644 | EFO_0007204 | B01 | — | 1 | — | — | — | 1 |
| Rubella | D012409 | B06 | — | 1 | — | — | — | 1 | |
| Cervical intraepithelial neoplasia | D018290 | D06 | — | 1 | — | — | — | 1 | |
| Uterine cervical neoplasms | D002583 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hookworm infections | D006725 | EFO_0007314 | B76 | 3 | — | — | — | — | 3 |
| Malaria | D008288 | EFO_0001068 | B54 | 3 | — | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | — | — | — | — | 2 | 2 | |
| Hepatitis b virus | D006515 | — | — | — | — | 2 | 2 | ||
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
| Pneumococcal infections | D011008 | EFO_0000772 | J13 | — | — | — | — | 2 | 2 |
| Celiac disease | D002446 | EFO_0001060 | K90.0 | — | — | — | — | 2 | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Hepatitis c | D006526 | B19.2 | — | — | — | — | 1 | 1 | |
| Intravenous substance abuse | D015819 | — | — | — | — | 1 | 1 | ||
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Risk-taking | D012309 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN |
| INN | — |
| Description | Heplisav B, PreHevbri (hepatitis b virus hbsag surface protein antigen) is an unknown pharmaceutical. Hepatitis b virus hbsag surface protein antigen was first approved as Heplisav b on 2021-02-18. It has been approved in Europe to treat hepatitis b. |
| Classification | Unknown |
| Drug class | antivirals |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297973 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 275 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more